Japanese startup RevolKa secures $1.4 M in Series A extension funding to advance drug discovery programmes for rare diseases, co-led by D3 LLC and TOHOKU University Venture Partners.
Japanese startup RevolKa secures $1.4 M in Series A extension funding to advance drug discovery programmes for rare diseases, co-led by D3 LLC and TOHOKU University Venture Partners.
05/20/25, 4:30 AM
Location
sendaiMoney raised
$1.4 million
Industry
biotechnology
Investors
Deepcore Inc., Tohoku University Venture Partners, D3 Llc
RevolKa Ltd. has raised $1.4 million in Series A extension funding to further its drug discovery programmes for rare diseases. This round was co-led by D3 LLC and TOHOKU University Venture Partners, with participation from DEEPCORE Inc. The funding will also support collaborative partnering efforts to enhance their AI-powered protein engineering technology
Company Info
Location
sendai, miyagi prefecture, japan
Additional Info
RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets.